Physician Withdrawal Checklist (PWC-20)
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Anxiety disorders are the most common mental illnesses in the United States. Despite having a number of medication options readily available, benzodiazepines (BZs) and antidepressants have achieved remission rates of only 35% after 8 weeks of acute treatment. In the development of new anxiolytics, particularly those that affect the gamma-aminobutyric acid system, it is essential to assess the new compound's potential to cause discontinuation symptoms after stopping the medication as part of both short- and long-term treatment. This report describes the development of the 20-item Penn Physician Withdrawal Checklist (PWC), a smaller version of the original 35-item PWC, and examines its validity, internal consistency, test-retest and interrater reliability, and factor structure. The PWC scores, assessed at the peak of withdrawal severity, were selected from 143 of our patients for an orthogonal factor analysis. Our results suggest that the Penn Physician Withdrawal Checklist is a simple and accurate method to assess anxiolytic discontinuation symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, the same definition has also been used previously in clinical studies 20,21 of patients with MDD who were selected irrespective of response to previous treatment.”
Citations
Cites
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
(2002) · PubMed · Cited by 518
The epidemiology of anxiety disorders: prevalence and societal costs.
Lépine, J. (2002) · PubMed · Cited by 396
Rickels, K. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290060008 · Cited by 384
Self-citationWithdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367 · cited 1×
“Items were added over time based either on our own clinical observation(16,17) or on reports in the literature.(18,19) In fact, most symptoms presently being used in the PWC were observed by us in the first ever reported double-blind case study of a patient who was, for 5 years, treated with 20 mg of diazepam daily(16…”
MethodLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 3×
“0001).(14) Test-retest reliability was assessed by correlating screen and baseline PWC-35 scores, assessed by the same psychiatrist, for 47 patients.”
MethodSelf-citationCarter, R. M., Wittchen, H.-U., Pfister, H., & Kessler, R. C. (2001) · Depression and Anxiety · doi:10.1002/da.1020 · Cited by 331
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 314
Long-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03340060045024 · Cited by 276
Self-citationLong-term Diazepam Therapy and Clinical Outcome
Rickels, K. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.250.6.767 · Cited by 276
Self-citation
Research works printed but not linked: 1
- Schoepf, 1981, Unusual withdrawal symptoms after long-term administration of benzodiazepines., Nervenarzt, 52, 288
Cited by
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
“No evidence of withdrawal symptoms was observed during the 2 weeks after cessation of treatment with esketamine/antidepressant assessed by Physician Withdrawal Checklist-20.”
MethodInfluentialOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Kasper, S., Gastpar, M., Müller, W. E., Volz, H.-P., Möller, H.-J., Schläfke, S., & Dienel, A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000017 · Cited by 216
“Moreover, withdrawal symptoms were ascertained by administering the Physician Withdrawal Checklist (PWC-20; Rickels et al., 2008) at the end of randomized treatment as well as after the down-titration phase.”
Silexan in anxiety disorders: Clinical data and pharmacological background
Kasper, S. F., Müller, W. E., Volz, H., Möller, H., Koch, E., & Dienel, A. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1331046 · Cited by 140
“The trial included patients suffering from GAD who had been administered either Silexan 80mg/day, Silexan 160mg/day, placebo, or paroxetine 20mg/day, and assessed values of the 20-item Physician Withdrawal (PWC-20) (Rickels et al. 2008) in all groups at the beginning and end of a 1-week down-titration phase.”
BackgroundMethodInfluentialCurrent use of benzodiazepines in anxiety disorders
Cloos, J.-M., & Ferreira, V. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831a473d · Cited by 127
Han, H., Ma, Y., Eun, J. S., Li, R., Hong, J. T., Lee, M. K., & Oh, K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.11.012 · Cited by 111
GABA and 5-HT systems are implicated in the anxiolytic-like effect of spinosin in mice
Liu, J., Wei-min, Z., Yang, Y., Shi, J., Liu, Q.-T., Guo-lin, L., Fang, N., Li, J., & Guo, J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.003 · Cited by 107
“Benzodiazepines have been used for the treatment of several forms of anxiety, but these compounds have well-known side effects, such as sedation, muscle relaxation, amnesia, and dependence potential (Gardner et al., 1993; Rickels et al., 2008; Youssef and Rich, 2008).”
BackgroundPharmacological treatment of generalized anxiety disorder
Reinhold, J. A., Mandos, L. A., Rickels, K., & Lohoff, F. W. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618496 · Cited by 90
“Aside from the obvious issue of potential dependence with prolonged use, benzodiazepines are also not desirable first-line therapies owing to the potential for withdrawal syndromes and rebound effects upon abrupt discontinuation [5,20,21].”
BackgroundSelf-citationRisk versus risk: a review of benzodiazepine reduction in older adults
Paquin, A. M., Zimmerman, K., & Rudolph, J. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.925444 · Cited by 82
“Tool Items User Scoring Comments Symptom Severity Patient Provider Scale Item BWSQ [18] X X X X 0 -- 40 0 (no) Allows for new symptom description 1 (moderate) Seek medical help: overall score > 20, new or severe symptoms 2 (severe) Change of 3 associated indicative of withdrawal symptoms CIWA-B [20] X X X X 0 -- 80 0…”
A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140291 · Cited by 71
“No clinically meaningful effects were observed in analyses of laboratory values, vital signs, ECG measurements, CSDD, or PWC-20, nor were any trends observed for ABT-288.”
Koblan, K. S., Hopkins, S. C., Sarma, K., Jin, F., Goldman, R., Kollins, S. H., & Loebel, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.124 · Cited by 62
“…Insomnia Severity Index (ISI; Bastien et al, 2001); risk of drug withdrawal was evaluated using the 20-item Physician Withdrawal Checklist (PWC; Rickels et al, 2008); an Abuse Potential Monitoring Plan was implemented that included monitoring of sentinel adverse events and medication handling…”
MethodKim, M., Nam, E. S., Lee, Y., & Kang, H. (2021) · Asian Nursing Research · doi:10.1016/j.anr.2021.11.001 · Cited by 98
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Kasper, S. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.813555 · Cited by 57
“In study G the Physician Withdrawal Checklist (PWC-20, Rickels et al. 2008), that was originally developed to detect benzodiazepine-like withdrawal symptoms caused by anxiolytics of the non-SSRI type, was evaluated at the end of the 10-week randomised treatment period as well as 1 week thereaft er.”
MethodPF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
Riesenberg, R. A., Werth, J. L., Zhang, Y., Duvvuri, S., & Gray, D. L. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420911296 · Cited by 57
Abrupt withdrawal of cannabidiol (CBD): A randomized trial
Taylor, L., Crockett, J. C., Tayo, B., Checketts, D., & Sommerville, K. W. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.106938 · Cited by 58
An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 47
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease
Marek, G. J., Katz, D. A., Meier, A., Greco, N., Zhang, W., Liu, W., & Lenz, R. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.010 · Cited by 42
Gault, L. M., Ritchie, C. W., Robieson, W. Z., Pritchett, Y., Othman, A. A., & Lenz, R. A. (2015) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.001 · Cited by 41
“Exploratory analyses indicated a statistically significantly higher LS mean PWC-20 score for the ABT-126 25 mg group (3.32, SE 5 0.38) compared with placebo (1.64, SE 5 0.38, P 5 .002).”
MethodInfluentialHaig, G. M., Wang, D., Othman, A. A., & Zhao, J. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.101 · Cited by 41
“Overall, no clinically meaningful changes were noted on physical exam, clinical laboratory, ECG, C-SSRS, movement rating scales (SAS, BAS, AIMS), or PWC-20 assessments.”
MethodChen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
“Other safety evaluations included the Columbia-Suicide Severity Rating Scale (C-SSRS) to assess potential suicidal ideation and behavior,(24) the Clinician-Administered Dissociative States Scale (CADSS) to assess dissociative symptoms,(25) and the 20-Item Physician Withdrawal Checklist (PWC-20) to assess potential wit…”
MethodLi, J., Liu, Q.-T., Chen, Y., Liu, J., Shi, J.-L., Liu, Y., & Guo, J.-Y. (2016) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2016/6530364 · Cited by 40
“Benzodiazepines are the most common drugs that have been used for the treatment of anxiety, but these compounds have obvious side effects, such as sedation, muscle relaxation, amnesia, and dependence potential [3–5].”
BackgroundClinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
Jeon, H. J., Ju, P., Sulaiman, A. H., Aziz, S. A., Paik, J., Tan, W., Bai, D., & Li, C. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.70 · Cited by 27
“Unlike the relatively stable scores for the total population and non-Asian subgroup, the scores for Asian subjects fluctuated randomly throughout the follow-up phase; with the PWC-WS scores appearing to be relatively more stable compared with its corresponding PWC-20 and PWC-DS scores.”
MethodInfluentialWłodarczyk, A., & Cubała, W. J. (2020) · Medicina · doi:10.3390/medicina56020067 · Cited by 25
“There is other evidence showing that the effects of oral ketamine are not as rapid as those associated with intravenous administration [20].”
BackgroundLevo-Tetrahydroberberrubine Produces Anxiolytic-Like Effects in Mice through the 5-HT1A Receptor
Mi, G., Liu, S., Zhang, J., Liang, H., Gao, Y., Li, N., Yu, B., Yang, H., & Zheng, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168964 · Cited by 20
Kosik‐Gonzalez, C., Fu, D., Chen, L. N., Lane, R., Bloch, M. H., DelBello, M. P., Moreno, C., Drevets, W. C., & Canuso, C. M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1016/j.jaac.2025.02.015 · Cited by 26
Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Whooley, E., McDonagh, K., McDonogh, S., Loughran, O., Shackleton, E., Igoe, A., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3019 · Cited by 25
Silexan does not cause withdrawal symptoms even when abruptly discontinued
Gastpar, M., Müller, W. E. G., Volz, H., Möller, H. ‐., Schläfke, S., Dienel, A., & Kasper, S. F. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1301488 · Cited by 18
“The PWC-20 was originally developed to detect benzodiazepine-like withdrawal symptoms caused by anxiolytics of the NON-SSRI type (Rickels et al. 2008).”
BackgroundMethodFava, M., Stahl, S. M., Pani, L., Martin, S. D., Cutler, A. J., Maletic, V., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Kosten, T. R., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15265 · Cited by 18
Effects of Pregabalin in Patients with Hypnotic-Dependent Insomnia
Cho, Y. W., & Song, M. L. (2014) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.3708 · Cited by 16
Kurhe, Y., Radhakrishnan, M., Devadoss, T., & Gupta, D. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.125186 · Cited by 15
“[2] This probably raise questions over the efficacy of the current therapeutic treatment or lack of understanding the neurobiological pathophysiology of anxiety disorder.[3] Since, last 3 decades, benzodiazepines (BZD) have been the drug of choice for anxiety treatment due to their effectiveness and relative safety.”
Schaffler, K., Yassen, A., Reeh, P. W., & Passier, P. C. C. M. (2017) · Pain Medicine · doi:10.1093/pm/pnx281 · Cited by 14
Stauffer, V. L., Baygani, S., Kinon, B. J., & Krikke-Workel, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000187 · Cited by 12
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7
“The most frequently used list of anxiolytic-associated symptoms is the Physician Withdrawal Checklist (PWC-20), but anecdotal reports of benzodiazepine-associated symptoms have appeared in the literature as well [22,74].”
Zhao, C.-B.-W., Liu, J., Shi, J., Wang, S., Ding, Y.-S., He, S., Lin, M.-X., Luo, J., Jiang, Y.-N., Bian, L.-H., et al. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2078932 · Cited by 6
Jelovac, A., McCaffrey, C., Terao, M., Shanahan, E., Mohamed, E., Whooley, E., McDonagh, K., McDonogh, S., Igoe, A., Loughran, O., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05365-9 · Cited by 7
“The 20-item Physician Withdrawal Checklist (PWC-20) [42] is used to assess for potential withdrawal symptoms during and after completing the allocated course of ketamine or midazolam infusions.”
BackgroundMethodTeuns, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420172-9.00005-9 · Cited by 6
Addictions aux benzodiazépines: prévalence, diagnostic et traitement
Cloos, J. M., Stein, R., Rauchs, P., Koch, P., & Chouinard, G. (2011) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(11)55586-5 · Cited by 8
Aluisio, L. E., Yieh, L., Wajs, E., DiBernardo, A., Krystal, A. D., Drevets, W. C., Wu, Y., Gogate, J. P., Daly, E., Zannikos, P., et al. (2020) · CNS Spectrums · doi:10.1017/s1092852920000589 · Cited by 5
Modeling the efficacy of a novel antidepressant zuranolone for major depressive disorder
Liu, J., Hong, L.-M., Qian, Y., Chen, R., & Lin, W.-W. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120158 · Cited by 2
Low Abuse Potential of Plant-Derived Highly Purified Cannabidiol: A Narrative Review
Yamamoto, H., Dayal, S., Nortvedt, C., & Takumi, I. (2025) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.25-00086 · Cited by 2
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_4 · Cited by 3
141 Moderating Perspectives of Long Acting Injectable Use of Antipsychotics: A Literature Review
Riedford, K. (2020) · CNS Spectrums · doi:10.1017/s1092852920000577 · Cited by 2
Anders, R., Chapoutot, M., Meloni, F., Peter‐Derex, L., Gustin, M., & Putois, B. (2024) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2024.100510 · Cited by 1
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_4-1 · Cited by 2
Aluisio, L. E., Wajs, E., DiBernardo, A., Chen, N., Drevets, W. C., Daly, E., Zannikos, P., Curran, V. H., Krystal, A., Chen, G., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.346 · Cited by 1
Bhatt, S., Devadoss, T., Jindal, A., & Mahesh, R. (2013) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.119855
Teuns, G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813724-6.00049-9
Current awareness: Pharmacoepidemiology and drug safety
(2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1493
Current awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.971
Abhängigkeitsschweregrad, Komorbidität und Kognition im Benzodiazepinentzug
Fischer, A. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4089 · Cited by 1
Cannabidiol (CBD): Abuse and physical dependence potential
Sommerville, K. W., & Setnik, B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00015-5
Priyam, A., Hill, A., ABDELLATIF, M., Ann, S. G. L., Ravindrarajah, R., Myo, N., Ko, N., Daly, C., & Kaar, S. J. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2689035
The Sequence of Clinical Development
Poole, R. M. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139032445.003 · Cited by 1
Metadata
- Authors
- Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W.
- Affiliations
- University of Pennsylvania (US)
- University of the Sciences (US)
- Corresponding author
- Rickels, Karl
- Mandos, Laura A.
- Case, George W.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-08
- Volume
- 28
- Issue
- 4
- Pages
- 447-451
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2081695582
- Cited by
- 59
- References
- 25
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 8 · 2019: 6 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 8 · 2013: 3 · 2012: 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-08957)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- benzodiazepine withdrawal, antidepressant discontinuation, anxiety disorders, psychometric validation, factor structure, internal consistency, inter-rater reliability, test-retest reliability
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Female, Humans, Male, Middle Aged, Physicians, Psychiatric Status Rating Scales, Psychometrics, Surveys and Questionnaires, Sensitivity and Specificity, Substance Withdrawal Syndrome, Anti-Anxiety Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.